ReviewAnnals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology2021
Immune-related cutaneous adverse events due to checkpoint inhibitors.
Review in Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04283539 (Identification of Pathways to Mitigate Immune-Related Adverse Events With Cancer Immunotherapy), which is not on this map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Identification of Pathways to Mitigate Immune-Related Adverse Events With Cancer Immunotherapy
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Real-World Cutaneous Immune-Related Adverse Events of Immunotherapy in Melanoma: A Systematic Review and Meta-Analysis.Dermatology and therapy · 2026Pooled it
- Topical ruxolitinib for prebullous phase of immune checkpoint Inhibitor-Induced bullous pemphigoid.JAAD case reports · 2026Article
- Comparative Clinical and Histological Analysis of Bullous Pemphigoid: Immunotherapy-Associated versus Spontaneous Onset Cases.Dermatology (Basel, Switzerland) · 2026Article
- The cutaneous mirror: leveraging drug-induced skin phenotypes as early visual risk signals for systemic toxicity, a comprehensive review.Frontiers in drug safety and regulation · 2026Review
- Real-world safety of first-line enfortumab vedotin plus pembrolizumab in advanced urothelial carcinoma: evidence from VigiBase and FAERS.Frontiers in immunology · 2026Article
- AI-enabled precision prediction and proactive management of cutaneous toxicities in cancer immunoradiotherapy (ICI+RT).Frontiers in oncology · 2026Review
- The Search for Predictive Biomarkers in Response to Immune Checkpoint Inhibitors and Associated Adverse Events.Journal of personalized medicine · 2025Review
- Real-World Effectiveness and Safety of Immune Checkpoint Inhibitors Combined with Chemotherapy in Taiwanese Patients with Extensive-Stage Small Cell Lung Cancer.Current oncology (Toronto, Ont.) · 2025Article
- Article
- Dermatologic toxicities related to cancer immunotherapy.Toxicology reports · 2025Article
- Article
- LC-OCT for early diagnosis and characterization of dermatologic adverse events to oncologic drugs and correlation to histopathology.International journal of dermatology · 2025Article
- Biomarkers associated with immune-related adverse events induced by immune checkpoint inhibitors.World journal of clinical oncology · 2024Review
- Immunologic Profiling of Immune-Related Cutaneous Adverse Events with Checkpoint Inhibitors Reveals Polarized Actionable Pathways.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Article
- Efficacy and safety of immune checkpoint inhibitors in solid tumor patients combined with chronic coronary syndromes or its risk factor: a nationwide multicenter cohort study.Cancer immunology, immunotherapy : CII · 2024Observational
- IL12/23 Blockade with Ustekinumab as a Treatment for Immune-Related Cutaneous Adverse Events.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Characterization and Prognostic Significance of Cutaneous Immune-Related Adverse Events in Indian Patients on Immune Checkpoint Inhibitor Therapy.Dermatology practical & conceptual · 2023Article
- Cutaneous Adverse Events of Systemic Melanoma Treatments: A Retrospective Single-Center Analysis.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Management of immune-related cutaneous adverse events with dupilumab.Journal for immunotherapy of cancer · 2023Article
- A case of pembrolizumab-induced pigmented purpuric dermatosis.JAAD case reports · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 1 country.
Funding
Abstract
objectiveTo familiarize the reader with the most common cutaneous adverse events with immune checkpoint inhibitors (CPIs) and their grading and treatment. DATA SOURCES: Recent research articles, relevant review articles, and case series/reports in English from the PubMed database mostly, from 2010 onward. STUDY SELECTIONS: Most data are from retrospective studies and case series. Older studies regarding the mechanism were included if they were of particular importance.
resultsAn understanding of this review should enable the reader to identify specific skin disorders in patients receiving immune CPIs, grade the adverse event, and be able to treat or refer the patient as needed.
conclusionAllergists/immunologists need to be familiar with these immune-related cutaneous adverse events because their incidence will increase with the ever-expanding use of CPIs and, in particular, because patients will certainly continue to be referred suspecting drug allergies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.